Cost-Effectiveness of Kidney Transplantation From DCD in Italy

被引:32
|
作者
Cavallo, M. G. [1 ]
Sepe, V. [2 ]
Conte, F. [3 ]
Abelli, M. [4 ]
Ticozzelli, E. [4 ]
Bottazzi, A. [5 ]
Geraci, P. M. [6 ]
机构
[1] Univ Commerciale Luigi Bocconi, CeRGAS, Milan, Italy
[2] Fdn IRCCS Policlin San Matteo, Nephrol Unit, I-27100 Pavia, Italy
[3] Osped Cernusco Sul Naviglio, Unit Nephrol & Dialysis, Cernusco Sul Naviglio, Italy
[4] Fdn IRCCS Policlin San Matteo, Unit Transplantat Surg, I-27100 Pavia, Italy
[5] Fdn IRCCS Policlin San Matteo, Intens Care Unit 2, I-27100 Pavia, Italy
[6] Fdn IRCCS Policlin San Matteo, I-27100 Pavia, Italy
关键词
STAGE RENAL-DISEASE; PERITONEAL-DIALYSIS; HEMODIALYSIS; RECIPIENTS; PERFUSION; EVENTS;
D O I
10.1016/j.transproceed.2014.09.146
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction. Kidney transplantation represents the best therapeutic option for patients with end-stage renal disease (ESRD), providing the best outcomes for survival, quality of life, and cost-effectiveness. To increase kidney donations, in 2007, the Italian IRCCS Policlinico San Matteo Foundation in Pavia designed and conducted Programma Alba, a protocol for organ donation after cardiac death (DCD). This study evaluated the costs and health outcomes of DCD transplantation and in all types of transplants compared with current clinical practice. Patients and Methods. A Markov-based model was used to assess costs and health outcomes for new ESRD patients for 2008 to 2013. A health care founder perspective was used. Data sources were the Italian National Institute of Statistics and the Lombardy Registry of Dialysis and Transplantation. A microcosting analysis was performed to calculate costs related to clinical pathways for DCD. We assessed costs, survival, quality-adjusted survival, and cost-effectiveness. Findings. Changing the actual practice pattern for new patients with ESRD and increasing the availability of kidneys from DCD to 10 extra transplants per year will induce an incremental cost per quality-adjusted life-year of (sic)4255. Increases in transplantation to reach an extra 10% by transplant type would result in reduced costs and increased patient survival and quality of life compared with the current scenario. Interpretation. Our data show that increasing DCD transplants would result in a cost-effective policy to expand the kidney donor pool compared with current ESRD treatment patterns. Italian policies should make an effort to increase transplant rates to optimize cost-effectiveness in ESRD service supply.
引用
收藏
页码:3289 / 3296
页数:8
相关论文
共 50 条
  • [1] DCD Kidney Transplantation: A Cost-Effectiveness Analysis
    Snyder, Rebecca A.
    Moore, Deonna R.
    Moore, Derek E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 66 - 66
  • [2] DCD Kidney Transplantation: A Cost-Effectiveness Analysis
    Snyder, R. A.
    Moore, D. R.
    Moore, D. E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 230 - 230
  • [3] COST-EFFECTIVENESS IN ITALY OF KIDNEY TRANSPLANTATION FROM DONORS AFTER CIRCULATORY DEATH
    Cavallo, Maria Caterina
    Sepe, Vincenzo
    Conte, Ferruccio
    Albrizio, Paolo
    Bottazzi, Andrea
    Geraci, Paolo Maria
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 500 - 500
  • [4] More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation
    Snyder, Rebecca A.
    Moore, Deonna R.
    Moore, Derek E.
    [J]. CLINICAL TRANSPLANTATION, 2013, 27 (02) : 289 - 296
  • [5] The cost-effectiveness of induction immunosuppression in kidney transplantation
    Morton, Rachael L.
    Howard, Kirsten
    Webster, Angela C.
    Wong, Germaine
    Craig, Jonathan C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (07) : 2258 - 2269
  • [6] Cost-Effectiveness of Protocol Biopsies in Kidney Transplantation
    Puttarajappa, C. M.
    Hariharan, S.
    Smith, K. J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 328 - 328
  • [7] COST-EFFECTIVENESS OF IMMUNOADSORPTION FOR INCOMPATIBLE KIDNEY TRANSPLANTATION IN GERMANY
    Kendzia, D.
    Busink, E.
    Apel, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S261 - S261
  • [8] COST-EFFECTIVENESS OF ANTIBODY INDUCTION IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION
    Morton, R. L.
    Howard, K.
    Webster, A. C.
    Wong, G.
    Craig, Jonathan C.
    [J]. NEPHROLOGY, 2008, 13 : A114 - A114